On March 7, 2024, Guangdong Tai'antang Pharmaceutical Co., Ltd. 002433) disclosed the "Risk Reminder Announcement on the Possible Termination of the Company's Listing", the company was previously unable to express an opinion due to the issuance of the 2022 annual financial and accounting report, and the company was implemented a "delisting risk warning".
Tai'an Tang (002433) disclosed the "2023 Annual Results Forecast" on January 31, 2024, and the expected performance loss from January 1, 2023 to December 31, 2023. The net profit loss attributable to shareholders of the listed company was 176,614$760,000 to $192,114760,000 yuan. It is worth noting that the Tai'an Tang (002433) misrepresentation case is ongoing, and investors who need to make a claim can continue to file a claim.
On December 28, 2023, Tai'an Tang (002433) announced that it received the "Administrative Penalty Decision" issued by the Guangdong Regulatory Bureau, and the company's regular report contained false records and major omissions, and was administratively punished by the CSRC. The statute of limitations for this case has not yet expired, and investors who meet the conditions for claiming can actively contact a lawyer to sign up for a claim. The Fasheng team pays the lawyer's fees, travel expenses and litigation fees for the investor, and the investor pays a certain percentage of the actual compensation after receiving the compensation from the listed company. If you are eligible for an injured investor, please contact us as soon as possible to register your claim.
Claim Conditions
Investors who sold or held** Tai'an Tang (002433) between April 10, 2019 and April 28, 2023 and sold or held ** after May 5, 2023 (inclusive) can register for a claim (the final result is subject to the court's determination).